Trial Profile
A Phase 1/2a, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Alpha galactosylceramide (Primary) ; Methotrexate; Mycophenolate mofetil; Sirolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors REGiMMUNE
- 01 Apr 2023 According to a REGiMMUNE media release, efficacy and safety results were presented at the ASH annual meeting on 5 Dec 2020 annual meeting in December 2022.
- 04 Feb 2021 Results published in the REGiMMUNE Media Release.
- 01 Apr 2017 Status changed from active, no longer recruiting to completed.